Search
Hovione expands nasal drug delivery capabilities with the development of nasal powder delivery device technology in collaboration with IDC
Hovione, the specialist integrated CDMO, just announced an expansion of its nasal drug delivery capabilities with the addition of a family of innovative nasal powder delivery devices developed in partnership with IDC.
Hovione awarded with the COTEC INNOVATIVE 2021 statute
Innovation potential in profitable growth and financial strength
Hovione Commits to Science-Based Targets for Greenhouse Gas (GHG) Emissions
Hovione commitment to setting SBTs in line with the Paris Agreement
Hovione completes its Phase 2 clinical trial of the first minocycline ophthalmic
Showing promise in Dry Eye Disease associated with Inflamed Meibomian Gland Dysfunction
Jean-Luc Herbeaux to become Hovione CEO
Hovione today announced the appointment of Dr. Jean-Luc Herbeaux as Hovione’s Chief Executive Officer, effective 1st April 2022
World Patient Safety Day 2021
Safety First, Quality Always: We are continuously improving the safety of our operations with the patient’s safety in mind.